cAMP-response Element-binding Protein Contributes to Suppression of the A2A Adenosine Receptor Promoter by Mutant Huntingtin with Expanded Polyglutamine Residues*

Huntington's disease is a neurodegenerative disease resulting from a CAG (glutamine) trinucleotide expansion in exon 1 of the Huntingtin (Htt) gene. The role of the striatum-enriched A2A adenosine receptor (A2A-R) in Huntington's disease has attracted much attention lately. In the present study, we found that expression of mutant Htt with expanded poly(Q) significantly reduced the transcript levels of the endogenous A2A-R in PC12 cells and primary striatal neurons. Cotransfection of various promoter constructs of the A2A-R gene and an expression construct of poly(Q)-expanded Htt revealed that the Htt mutant suppressed the core promoter activity of the A2A-R gene. Stimulation of the A2A-R using CGS21680, forskolin, and a constitutively active cAMP-response element-binding protein (CREB) mutant elevated the reduced promoter activity of the A2A-R gene by mutant Htt. Moreover, the effect of CGS was blocked by an A2A-R-selective antagonist (CSC), two inhibitors of protein kinase A, and two dominant negative mutants of (CREB). The protein kinase A/CREB pathway therefore is involved in regulating A2A-R promoter activity. Consistently, an atypical CRE site (TCCAGG) is located in the core promoter region of the A2A-R gene. Electrophoretic gel mobility shift assay and mutational inactivation further demonstrated the functional binding of CREB to the core promoter region and showed that expression of poly(Q)-expanded Htt abolished the binding of CREB to this site. Stimulation of the A2A-R restored the reduced CREB binding caused by the mutant and concurrently reduced mutant Htt aggregation. Collectively, the poly(Q)-expanded mutant Htt suppressed expression of the A2A-R by inhibiting its core promoter at least partially by preventing CREB binding.

[1]  D. Ginty,et al.  Nerve growth factor-induced neuronal differentiation after dominant repression of both type I and type II cAMP-dependent protein kinase activities. , 1991, The Journal of biological chemistry.

[2]  U. Ungerstedt,et al.  The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[3]  M. Jacobson,et al.  Adenosine A2a receptor activation delays apoptosis in human neutrophils. , 1997, Journal of immunology.

[4]  N. Nukina,et al.  Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease , 2004, Nature Medicine.

[5]  Peter Breuer,et al.  Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. , 2004, Molecular cell.

[6]  K. Varani,et al.  The FASEB Journal express article 10.1096/fj.00-0730fje. Published online March 5, 2001. Aberrant amplification of A2A receptor signaling in striatal cells expressing mutant huntingtin , 2022 .

[7]  Y. Chern,et al.  Protein Kinase C Inhibits Adenylyl Cyclase Type VI Activity during Desensitization of the A2a-Adenosine Receptor-mediated cAMP Response* , 1997, The Journal of Biological Chemistry.

[8]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[9]  D. Housman,et al.  The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  S. Schiffmann,et al.  A Dual Role of Adenosine A2A Receptors in 3-Nitropropionic Acid-Induced Striatal Lesions: Implications for the Neuroprotective Potential of A2A Antagonists , 2003, The Journal of Neuroscience.

[11]  D. Rubinsztein,et al.  Raised intracellular glucose concentrations reduce aggregation and cell death caused by mutant huntingtin exon 1 by decreasing mTOR phosphorylation and inducing autophagy. , 2003, Human molecular genetics.

[12]  He Li,et al.  Interaction of Huntington Disease Protein with Transcriptional Activator Sp1 , 2002, Molecular and Cellular Biology.

[13]  K. Varani,et al.  Aberrant A2A receptor function in peripheral blood cells in Huntington's disease , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  L. Farrell,et al.  Mutant huntingtin increases nuclear corepressor function and enhances ligand-dependent nuclear hormone receptor activation , 2003, Molecular and Cellular Neuroscience.

[15]  J. Kiang,et al.  Regulation of heat shock protein 72 kDa and 90 kDa in human breast cancer MDA-MB-231 cells , 2004, Molecular and Cellular Biochemistry.

[16]  Y. Chern,et al.  Identification of nuclear factor 1 (NF1) as a transcriptional modulator of rat A(2A) adenosine receptor. , 2003, Brain research. Molecular brain research.

[17]  E. Schwarz,et al.  CREB Cooperates with BMP‐stimulated Smad signaling to enhance transcription of the Smad6 promoter , 2004, Journal of cellular physiology.

[18]  M. Dragunow,et al.  The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease , 2000, Neuroscience.

[19]  Y. Chern,et al.  Characterization of the rat A2a adenosine receptor gene. , 1996, DNA and cell biology.

[20]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[21]  C. Ross,et al.  Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein. , 2003, Human molecular genetics.

[22]  Y. Chern,et al.  The 5' Untranslated Regions of the Rat A2A Adenosine Receptor Gene Function as Negative Translational Regulators , 1999, Journal of neurochemistry.

[23]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[24]  Ruth Luthi-Carter,et al.  Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice , 2003, The Journal of Neuroscience.

[25]  Y. Chern,et al.  Molecular cloning of a novel adenosine receptor gene from rat brain. , 1992, Biochemical and biophysical research communications.

[26]  Andrea Crotti,et al.  Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes , 2003, Nature Genetics.

[27]  J. Olson,et al.  Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. , 2002, Human molecular genetics.

[28]  Y. Chern,et al.  Activation of Protein Kinase A and Atypical Protein Kinase C by A2A Adenosine Receptors Antagonizes Apoptosis Due to Serum Deprivation in PC12 Cells* , 2001, The Journal of Biological Chemistry.

[29]  C. Vinson,et al.  PTHrP Modulates Chondrocyte Differentiation through AP-1 and CREB Signaling* , 2001, The Journal of Biological Chemistry.

[30]  R. Ferrante,et al.  Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3‐nitropropionic acid‐induced striatal damage , 2003, Journal of neurochemistry.

[31]  C A Ross,et al.  Interference by Huntingtin and Atrophin-1 with CBP-Mediated Transcription Leading to Cellular Toxicity , 2001, Science.

[32]  Y. Chern,et al.  Multiple mechanisms for desensitization of A2a adenosine receptor-mediated cAMP elevation in rat pheochromocytoma PC12 cells. , 1993, Molecular pharmacology.

[33]  D. Rubinsztein,et al.  Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. , 2001, Human molecular genetics.

[34]  M. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[35]  J. Cha,et al.  Transcriptional dysregulation in Huntington’s disease , 2000, Trends in Neurosciences.

[36]  M. Caporali,et al.  CGS 21680 antagonizes motor hyperactivity in a rat model of Huntington's disease. , 1994, European journal of pharmacology.

[37]  J. Nevins,et al.  Huntingtin Is Present in the Nucleus, Interacts with the Transcriptional Corepressor C-terminal Binding Protein, and Represses Transcription* , 2002, The Journal of Biological Chemistry.

[38]  D. Rubinsztein,et al.  Decreased cAMP Response Element-mediated Transcription , 2004, Journal of Biological Chemistry.

[39]  M. Falchi,et al.  Blockade of Striatal Adenosine A2A Receptor Reduces, through a Presynaptic Mechanism, Quinolinic Acid-Induced Excitotoxicity: Possible Relevance to Neuroprotective Interventions in Neurodegenerative Diseases of the Striatum , 2002, The Journal of Neuroscience.

[40]  J. Olson,et al.  Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. , 2002, Human molecular genetics.

[41]  M. Umemiya,et al.  A Calcium-Dependent Feedback Mechanism Participates in Shaping Single NMDA Miniature EPSCs , 2001, The Journal of Neuroscience.

[42]  Wolfgang Schmid,et al.  Disruption of CREB function in brain leads to neurodegeneration , 2002, Nature Genetics.

[43]  Changyuan Huang,et al.  CREB Is One Component of the Binding Complex of the Ces-2/E2A-HLF Binding Element and Is an Integral Part of the Interleukin-3 Survival Signal , 2001, Molecular and Cellular Biology.

[44]  M. Chiang,et al.  Characterization of the rat A2A adenosine receptor gene: a 4.8‐kb promoter‐proximal DNA fragment confers selective expression in the central nervous system , 2003, The European journal of neuroscience.

[45]  Dimitri Krainc,et al.  Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease , 2002, Science.

[46]  D. Weaver A2a adenosine receptor gene expression in developing rat brain. , 1993, Brain research. Molecular brain research.